Abstract: Objective To study the characteristics of clinical use of Shengmai Injection in the real world, and to provide reference for standardizing its clinical use. Methods Based on the hospital information system, 1014 cases of inpatients who received Shengmai Injection between October 1, 2017 and May 31, 2019 were selected and their basic information, diagnostic data, clinical drug use, drug combinations and adverse drug reactions were analyzed with statistical software before association analysis of combined medications was performed by the Apriori algorithm. Results 560 of these cases were male (55.23%), 454 were female (44.77%), and the average age was 62.67 years old. Most of them were treated in Departments of Endocrinology, Emergency and Neurology. Shengmai Injection was mainly used for diabetes mellitus in western medicine, but for Xiao Ke disease(446 cases,43.98%)with syndromes of both Qi -Yin deficiency(450 cases,44.38%) in TCM. All the patients were administered by intravenous drip with a single dose of 20-60ml (96.8%). The course of treatment usually lasted 1-14 days (97.69%) with an average of 5.7 days. The drugs most commonly used in combination with Shengmai Injection were insulin injection, metformin tablets and atorvastatin calcium tablets. Conclusion The clinical use of Shengmai Injection conforms to theories of TCM. The usage and dosage basically follow drug instructions and the combination of drugs is relatively well-grounded. However, off-label use can be found so that doctors should standardize drug use and ensure the safety of medication.

Key words: Shengmai injection, real-world study, characteristics medication